Contineum Therapeutics Inc (Class A) Live Stock Price Today, Share Analysis and Chart

Name: Contineum Therapeutics Inc. - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: Contineum Therapeutics Inc. - Ordinary Shares - Class A
Rating: 1.70066675
Author: Trendlyne DVM scores

about

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIP...

10.98 -0.14 (-1.26%)

28.00% Fall from 52W High

86,569

XNAS Volume

XNAS 04 Dec, 2025 4:30 PM (EST)

Not Eligible

Expensive Valuation

11.2 / 100

Technically Neutral

56.9 / 100

1Yr Price target upside is 166%

4 analysts

Contineum Therapeutics Inc (Class A) Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Contineum Therapeutics Inc (Class A) Live Stock Price Today, Share Analysis and Chart

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIP...

28.00% Fall from 52W High

SWOT Analysis

Contineum Therapeutics Inc (Class A) Live Price Chart